Shares of Agios Pharmaceuticals closed the previous trading session at 50.36 down -5.15 -9.28% with 1,285,084 shares trading hands. They now have a Dollars 54 price target on the stock. Its quick ratio for most recent quarter is 6.30 along with current ratio for most recent quarter of 6.30. Hanseatic Mngmt invested in 0.31% or 13,082 shares. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. We have $49.28 PT which if reached, will make NASDAQ:AGIO worth $110.00 million less. BB Biotech AG increased its position in shares of Agios Pharmaceuticals by 12.1% in the third quarter.
Another critical number in evaluating a stock is P/E or the price to earnings ratio. Finally, Beech Hill Advisors Inc. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at $217,000. On Friday, March 3 NELSEN ROBERT sold $2.06M worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) or 40,599 shares. Agios Pharmaceuticals, Inc. (AGIO) is a part of Healthcare sector and belongs to Biotechnology industry. Typically, a stock scoring an 8 or 9 would be seen as strong while a stock with a score from 0-2 would be viewed as weak. Agios Pharmaceuticals has recorded a 50-day average of $53.56 and a two hundred day average of $50.53. Agios Pharmaceuticals Inc has a one year low of $35.84 and a one year high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 16th. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report 0.12 earnings per share. The company earned $22.65 million during the quarter, compared to analysts' expectations of $10.89 million. In comparison, a year ago the company earned revenue of $31.28 million and had a GAAP net loss of $23.2 million. The stock has earnings growth of -24.30% yoy and showed a high EPS growth of 10.60% over the past five years.More news: Killer of NFL's Will Smith gets 25 years for manslaughter
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) yearly performance is -0.16%.
COPYRIGHT VIOLATION NOTICE: This news story was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of U.S. & worldwide copyright & trademark laws. Zacks Investment Research cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday. The research firm, a subsidiary of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time.
05/18/2016 - Agios Pharmaceuticals, Inc. had its " rating reiterated by analysts at SunTrust. Further, analysts have a 12 month target price of $62.89 on company shares.More news: Pence In South Korea, Visits DMZ And US Troops
05/18/2016 - Agios Pharmaceuticals, Inc. had its "outperform" rating reiterated by analysts at Credit Suisse. Finally, Cann upgraded shares of Agios Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $75.00 price objective for the company in a research report on Tuesday, January 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock.
Yandex NV (NASDAQ:YNDX) stock price declined -2.87% to finalize at $23.32 throughout previous buying and selling session. They now have a United States dollars 135 price target on the stock. The shares were sold at an average price of $55.00, for a total value of $354,090.00. Following the transaction, the chief executive officer now directly owns 3,000 shares in the company, valued at approximately $175,860. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The stock has relative volume of 7.98. Moreover, Stonehill Capital Management Llc has 4.54% invested in the company for 965,759 shares. The disclosure for this sale can be found here.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.More news: Polar bear dies unexpectedly at SeaWorld San Diego
06/13/2016 - Agios Pharmaceuticals, Inc. was upgraded to "overweight" by analysts at JP Morgan. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes.
- Hospital: Seattle officer in critical condition
- I won't say whether we sabotaged North Korea missile test
- Tories lead in latest United Kingdom opinion poll
- New Trump Order Extends 'Buy American' And 'Hire American' Rules
- United Airlines can't say if video has hit sales
- Barcelona out of the UEFA Champions League
- Trudeau defends Canada's dairy system against Trump protectionist charge
- There's evidence! The Pill does make women feel lousy
- Diet soda study looks at dementia, heart risks
- GNC Stock Soars 28% Despite Mixed Q1 Earnings